These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 22659123)

  • 1. Risks and untoward toxicities of antibody-based immunoconjugates.
    Litvak-Greenfeld D; Benhar I
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1782-99. PubMed ID: 22659123
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different toxicity profiles for drug- versus radionuclide-conjugated BR96 monoclonal antibodies in a syngeneic rat colon carcinoma model.
    Nilsson R; Eriksson SE; Sjögren HO; Tennvall J
    Acta Oncol; 2011 Jun; 50(5):711-8. PubMed ID: 21214493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted cancer therapy: conferring specificity to cytotoxic drugs.
    Chari RV
    Acc Chem Res; 2008 Jan; 41(1):98-107. PubMed ID: 17705444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antibody conjugates and therapeutic strategies.
    McCarron PA; Olwill SA; Marouf WM; Buick RJ; Walker B; Scott CJ
    Mol Interv; 2005 Dec; 5(6):368-80. PubMed ID: 16394252
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoclonal antibody therapy for cancer.
    von Mehren M; Adams GP; Weiner LM
    Annu Rev Med; 2003; 54():343-69. PubMed ID: 12525678
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Application of monoclonal antibody for drug delivery system--missile therapy for cancer].
    Yamaguchi T; Takahashi T; Kitamura K; Otsuji E; Sakakura C; Okamoto K; Tsuruta H; Ichikawa D; Matsumura H; Yamamoto K; Nishida T; Kimura A
    Nihon Rinsho; 1998 Mar; 56(3):638-43. PubMed ID: 9549349
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potent antibody drug conjugates for cancer therapy.
    Senter PD
    Curr Opin Chem Biol; 2009 Jun; 13(3):235-44. PubMed ID: 19414278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Antibody-drug conjugates for cancer.
    Chau CH; Steeg PS; Figg WD
    Lancet; 2019 Aug; 394(10200):793-804. PubMed ID: 31478503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Small Antibody Fragments as Strategy to Deliver Therapeutic Payloads.
    Aguiar S; Dias J; Manuel AM; Russo R; Gois PMP; da Silva FA; Goncalves J
    Adv Protein Chem Struct Biol; 2018; 112():143-182. PubMed ID: 29680236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Alphav integrin-targeted immunoconjugates regress established human tumors in xenograft models.
    Chen Q; Millar HJ; McCabe FL; Manning CD; Steeves R; Lai K; Kellogg B; Lutz RJ; Trikha M; Nakada MT; Anderson GM
    Clin Cancer Res; 2007 Jun; 13(12):3689-95. PubMed ID: 17575234
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antibody-cytotoxic agent conjugates for cancer therapy.
    Chen J; Jaracz S; Zhao X; Chen S; Ojima I
    Expert Opin Drug Deliv; 2005 Sep; 2(5):873-90. PubMed ID: 16296784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of antibody, drug and linker on the preclinical and clinical toxicities of antibody-drug conjugates.
    Donaghy H
    MAbs; 2016; 8(4):659-71. PubMed ID: 27045800
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Human toxin-based recombinant immunotoxins/chimeric proteins as a drug delivery system for targeted treatment of human diseases.
    Lorberboum-Galski H
    Expert Opin Drug Deliv; 2011 May; 8(5):605-21. PubMed ID: 21453191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody conjugate therapeutics: challenges and potential.
    Teicher BA; Chari RV
    Clin Cancer Res; 2011 Oct; 17(20):6389-97. PubMed ID: 22003066
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody-drug conjugates as targeted cancer therapeutics.
    Sun Y; Yu F; Sun BW
    Yao Xue Xue Bao; 2009 Sep; 44(9):943-52. PubMed ID: 20055167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody drug conjugates under investigation in phase I and phase II clinical trials for gastrointestinal cancer.
    Leal AD; Krishnamurthy A; Head L; Messersmith WA
    Expert Opin Investig Drugs; 2018 Nov; 27(11):901-916. PubMed ID: 30359534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Toxicity-reducing potential of extracorporeal affinity adsorption treatment in combination with the auristatin-conjugated monoclonal antibody BR96 in a syngeneic rat tumor model.
    Nilsson R; Mårtensson L; Eriksson SE; Sjögren HO; Tennvall J
    Cancer; 2010 Feb; 116(4 Suppl):1033-42. PubMed ID: 20127954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunoconjugates against solid tumors: mind the gap.
    Ricart AD
    Clin Pharmacol Ther; 2011 Apr; 89(4):513-23. PubMed ID: 21368753
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies.
    Ducry L; Stump B
    Bioconjug Chem; 2010 Jan; 21(1):5-13. PubMed ID: 19769391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunoconjugates in drug delivery systems.
    Cannon JB; Hui HW
    Targeted Diagn Ther; 1990; 3():121-39. PubMed ID: 2131008
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.